HC Wainwright Issues Pessimistic Outlook for KYTX Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Equities researchers at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Kyverna Therapeutics in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($0.92) for the quarter, down from their previous forecast of ($0.89). HC Wainwright currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q3 2025 earnings at ($0.77) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.56) EPS.

Separately, Morgan Stanley reduced their price objective on Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $18.33.

Kyverna Therapeutics Stock Down 7.5%

Shares of Kyverna Therapeutics stock opened at $2.21 on Wednesday. The stock has a market cap of $95.51 million, a PE ratio of -0.65 and a beta of 2.17. Kyverna Therapeutics has a 12 month low of $1.78 and a 12 month high of $16.64. The business has a fifty day simple moving average of $2.13 and a 200-day simple moving average of $3.22.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Tuesday, May 13th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.21) by $0.18.

Hedge Funds Weigh In On Kyverna Therapeutics

Several institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of Kyverna Therapeutics in the fourth quarter worth about $34,000. Squarepoint Ops LLC bought a new position in shares of Kyverna Therapeutics in the fourth quarter worth about $43,000. Corton Capital Inc. bought a new position in shares of Kyverna Therapeutics in the fourth quarter worth about $45,000. Corebridge Financial Inc. increased its stake in shares of Kyverna Therapeutics by 42.3% in the fourth quarter. Corebridge Financial Inc. now owns 12,811 shares of the company’s stock worth $48,000 after purchasing an additional 3,810 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Kyverna Therapeutics by 53.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,288 shares of the company’s stock worth $53,000 after purchasing an additional 4,990 shares during the period. 18.08% of the stock is currently owned by institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.